Easy revenue. It may well appear like an elusive aspiration. Having said that, buyers actually have a good deal of alternatives to make funds without expending a whole lot of exertion.

Dividend stocks specifically stand out as an straightforward way to create recurring money. And you don’t have to give up on possibilities for growth with some dividend stocks. I can individually attest to this. These 5 stocks have reliable long-expression growth potential customers and will make me around $3,000 in passive revenue this year.

Picture supply: Getty Photographs.

1. AbbVie

I have 117 shares of AbbVie ( ABBV -1.88% ). The massive drugmaker at this time pays a dividend that totals $5.42 on an annualized foundation. That means that my stake in AbbVie should really make me a minor about $634 in cash flow in 2022.

Am I anxious that AbbVie’s best-advertising drug, Humira, faces the loss of exclusivity in the U.S. up coming 12 months? Not at all. Humira’s sales will sink but would not evaporate. AbbVie has other medicines in its lineup that must enable the firm to speedily return to growth. 

2. Brookfield Infrastructure

This a single is a minor challenging. Brookfield Infrastructure Companions ( BIP .14% ) (BIP) and Brookfield Infrastructure Corporation ( BIPC .53% ) (BIPC) share the exact same fundamental business enterprise. I to begin with bought BIP a couple a long time ago but been given shares of BIPC when it was developed to attract traders who wished to avoid the tax hassles related with restricted partnerships.

My portfolio now involves 259 shares of BIP and 26 shares of BIPC. The two stocks spend a dividend of $2.16 on an annualized basis. With each other, they need to supply just about $616 in income for me this yr.

Brookfield Infrastructure owns infrastructure belongings throughout the world, which includes mobile towers, details facilities, railroads, ports, toll roadways, and additional. These companies create steady and reliable cash movement for funding these dividends. And there are a great deal of expansion chances with infrastructure globally as nicely.

3. Devon Energy

Devon Strength ( DVN 6.18% ) delivers a mounted-moreover-variable dividend that the business expects will generate all around 8% this calendar year. Primarily based on this estimate, my 260 shares of the electricity inventory should really make me in the ballpark of $1,140 in dividend money in 2022.

Could the variable portion of Devon’s dividend be decreased than expected? It’s possible, but I doubt it. The firm employs up to 50% of its extra free money move for its variable dividend. With the latest marketplace dynamics in the oil and gas market, Devon need to improve its cost-free cash flow by at least 70% this year.

4. Ground breaking Industrial Attributes

I anticipate to obtain another $318 in dividends from my 53 shares of Innovative Industrial Properties ( IIPR -2.69% ) in 2022. That total could be even larger, looking at that the hashish-focused actual estate expense trust (REIT) frequently increases its dividend. In just the past three several years, IIP’s dividend payout has extra than tripled.

This is a stock that’s also possible to produce solid gains. IIP tends to make its revenue by acquiring qualities from cannabis operators then leasing the attributes again to the operators. The a lot more qualities it has, the additional income IIP will make. The enterprise included 31 attributes since Oct. 1, 2021, growing the overall properties in its portfolio by practically 42%.

5. Pfizer

Pfizer ( PFE -1.53% ) strategies to pay quarterly dividends that will overall $1.60 this yr. My 216 shares of the huge pharmaceutical business really should make me virtually $346 in dividend money.

I believe the prospective clients that Pfizer’s share selling price will shift higher this yr also look very excellent. The stock currently trades at only 7.5 situations expected earnings. Pfizer’s formal direction is for complete income of around $100 billion in 2022. But the company appears to be seriously lowballing its outlook for the profits of COVID-19 capsule Paxlovid. My hunch is that the drug will make a whole lot a lot more than $22 billion — and give some good catalysts for Pfizer with its quarterly updates this yr. 

Incorporating it up

Combined, these 5 shares really should give me passive profits of all-around $3,050 in 2022. In scenario you were being wondering, my blended once-a-year generate tops 4.5%.

I didn’t invest in these shares entirely mainly because of their dividends. I think the firms have reliable lengthy-time period expansion potential clients as perfectly. But to make about $3,000 this calendar year without having executing something — that is simple money.

This posting represents the feeling of the writer, who could disagree with the “official” recommendation position of a Motley Fool premium advisory support. We’re motley! Questioning an investing thesis – even just one of our own – aids us all feel critically about investing and make decisions that support us become smarter, happier, and richer.

By Anisa